Cdc25-dependent activation of cyclin A/cdk2 is blocked in G2 phase arrested cells independently of ATM/ATR

Abstract

Cyclin A/cdk2 is active during S and G2 phases of the cell cycle, but its regulation and function during G2 phase is poorly understood. In this study we have examined the regulation of cyclin A/cdk2 activity during normal G2 phase progression and in genotoxin-induced G2 arrest. We show that cyclin A/cdk2 is activated in early G2 phase by a cdc25 activity. In the G2 phase checkpoint arrest initiated in response to various forms of DNA damage, the cdc25-dependent activation of both cyclin A/cdk2 and cyclin B1/cdc2 is blocked. Ectopic expression of cdc25B, but not cdc25C, in G2 phase arrested cells efficiently activated both cyclin A/cdk2 and cyclin B1/cdc2. Finally, we demonstrate that the block in cyclin A/cdk2 activation in the G2 checkpoint arrest is independent of ATM/ATR. We speculate that the ATM/ATR-independent block in G2 phase cyclin A/cdk2 activation may act as a further layer of checkpoint control, and that blocking G2 phase cyclin A/cdk2 activation contributes to the G2 phase checkpoint arrest.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 7
Figure 6
Figure 8
Figure 9
Figure 10
Figure 11

References

  1. Badie C, Itzhaki JE, Sullivan MJ, Carpenter AJ and Porter AC. . 2000 Mol. Cell. Biol. 20: 2358–2366.

  2. Baldin V, Cans C, Knibiehler M and Ducommun B. . 1997 J. Biol. Chem. 272: 32731–32734.

  3. Blasina A, Price BD, Turenne GA and McGowan CH. . 1999 Curr. Biol. 9: 1135–1138.

  4. Blomberg I and Hoffmann I. . 1999 Mol. Cell. Biol. 19: 6183–6194.

  5. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW and Vogelstein B. . 1998 Science 282: 1497–1501.

  6. De Souza CP, Ellem KA and Gabrielli BG. . 2000 Exp. Cell. Res. 257: 11–21.

  7. Dulic V, Lees E and Reed SI. . 1992 Science 257: 1958–1961.

  8. Dulic V, Stein GH, Far DF and Reed SI. . 1998 Mol. Cell. Biol. 18: 546–557.

  9. Elledge SJ. . 1996 Science 274: 1664–1672.

  10. Forrest AR, McCormack AK, DeSouza CP, Sinnamon JM, Tonks ID, Hayward NK, Ellem KA and Gabrielli BG. . 1999 Biochem. Biophys. Res. Commun. 260: 510–515.

  11. Furnari B, Rhind N and Russell P. . 1997 Science 277: 1495–1497.

  12. Furuno N, den Elzen N and Pines J. . 1999 J. Cell. Biol. 147: 295–306.

  13. Gabrielli BG, Clark JM, McCormack AK and Ellem KA. . 1997a J. Biol. Chem. 272: 28607–28614.

  14. Gabrielli BG, Clark JM, McCormack AK and Ellem KA. . 1997b Oncogene 15: 749–758.

  15. Gabrielli BG, De Souza CP, Tonks ID, Clark JM, Hayward NK and Ellem KA. . 1996 J. Cell. Sci. 109: 1081–1093.

  16. Gabrielli BG, Sarcevic B, Sinnamon J, Walker G, Castellano M, Wang XQ and Ellem KA. . 1999 J. Biol. Chem. 274: 13961–13969.

  17. Gu Y, Rosenblatt J and Morgan DO. . 1992 EMBO J. 11: 3995–4005.

  18. Herzinger T, Funk JO, Hillmer K, Eick D, Wolf DA and Kind P. . 1995 Oncogene 11: 2151–2156.

  19. Innocente SA, Abrahamson JL, Cogswell JP and Lee JM. . 1999 Proc. Natl. Acad. Sci. USA 96: 2147–2152.

  20. Jin P, Gu Y and Morgan DO. . 1996 J. Cell. Biol. 134: 963–970.

  21. Jin P, Hardy S and Morgan DO. . 1998 J. Cell. Biol. 141: 875–885.

  22. Karlsson C, Katich S, Hagting A, Hoffmann I and Pines J. . 1999 J. Cell. Biol. 146: 573–584.

  23. Koff A, Giordano A, Desai D, Yamashita K, Harper JW, Elledge S, Nishimoto T, Morgan DO, Franza BR and Roberts JM. . 1992 Science 257: 1689–1694.

  24. Lammer C, Wagerer S, Saffrich R, Mertens D, Ansorge W and Hoffmann I. . 1998 J. Cell Sci. 111: 2445–2453.

  25. Lock RB. . 1992 Cancer Res. 52: 1817–1822.

  26. Lock RB, Galperina OV, Feldhoff RC and Rhodes LJ. . 1994 Cancer Res. 54: 4933–4939.

  27. Maity A, Hwang A, Janss A, Phillips P, McKenna WG and Muschel RJ. . 1996 Oncogene 13: 1647–1657.

  28. Millar JBA, Blevitt J, Gerace L, Sadhu K, Featherstone C and Russell P. . 1991 Proc. Natl. Acad. Sci. USA 88: 10500–10504.

  29. Milligan A, Gabrielli BG, Clark JM, NK H and Ellem KAO. . 1998 Mut. Res. 422: 43–53.

  30. Morgan DO. . 1997 Annu. Rev. Cell. Dev. Biol. 13: 261–291.

  31. Niculescu AB, 3rd, Chen X, Smeets M, Hengst L, Prives C and Reed SI. . 1998 Mol. Cell. Biol. 18: 629–643.

  32. O'Connell MJ, Raleigh JM, Verkade HM and Nurse P. . 1997 EMBO J. 16: 545–554.

  33. O'Connell MJ, Walworth NC and Carr AM. . 2000 Trends Cell. Biol. 10: 296–303.

  34. Pagano M, Pepperkok R, Lukas J, Baldin V, Ansorge W, Bartek J and Draetta G. . 1993 J. Cell. Biol. 121: 101–111.

  35. Pagano M, Pepperkok R, Verde F, Ansorge W and Draetta G. . 1992 EMBO J. 11: 961–971.

  36. Peng CY, Graves PR, Thoma RS, Wu Z, Shaw AS and Piwnica-Worms H. . 1997 Science 277: 1501–1505.

  37. Raleigh JM and O'Connell MJ. . 2000 J. Cell. Sci. 113: 1727–1736.

  38. Ramsay J, Birrell G, Baumann K, Bodero A, Parsons P and Lavin M. . 1998 Br. J. Cancer 77: 11–14.

  39. Rhind N, Furnari B and Russell P. . 1997 Genes Dev. 11: 504–511.

  40. Rosenblatt J, Gu Y and Morgan DO. . 1992 Proc. Natl. Acad. Sci. USA 89: 2824–2828.

  41. Sexl V, Diehl JA, Sherr CJ, Ashmun R, Beach D and Roussel MF. . 1999 Oncogene 18: 573–582.

  42. Tamura K, Southwick EC, Kerns J, Rosi K, Carr BI, Wilcox C and Lazo JS. . 2000 Cancer Res. 60: 1317–1325.

  43. Toyoshima F, Moriguchi T, Wada A, Fukuda M and Nishida E. . 1998 EMBO J. 17: 2728–2735.

  44. Walker DH, Adami GR, Dold KM and Babiss LE. . 1995 Cell Growth Differ. 6: 1053–1061.

  45. Wang XQ, Gabrielli BG, Milligan A, Dickinson JL, Antalis TM and Ellem KA. . 1996 Cancer Res. 56: 2510–2514.

Download references

Acknowledgements

We thank Dr J Lazo for the compound 5 cdc25 inhibitor and Dr David Morgan for the cdk2 wt and AF constructs. This study was supported by grants from the Queensland Cancer Fund and the National Health and Medical Research Council of Australia. S Goldstone was supported as a CJ Martin Fellow of the National Health and Medical Research Council of Australia. B Gabrielli is an Australian Research Council Fellow.

Author information

Correspondence to B Gabrielli.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Goldstone, S., Pavey, S., Forrest, A. et al. Cdc25-dependent activation of cyclin A/cdk2 is blocked in G2 phase arrested cells independently of ATM/ATR. Oncogene 20, 921–932 (2001). https://doi.org/10.1038/sj.onc.1204177

Download citation

Keywords

  • cell cycle checkpoint
  • DNA damage
  • ATM/ATR

Further reading